ARVINAS, INC. Treasury Stock Acquired, Average Cost Per Share
ARVINAS, INC. (ARVN) reported Treasury Stock Acquired, Average Cost Per Share of $9.09 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2026-02-24
- ARVINAS, INC. treasury stock acquired, average cost per share for the quarter ending 2025-09-30 was $7.91.
- ARVINAS, INC. treasury stock acquired, average cost per share for fiscal 2025 was $9.09.
| Period end | Treasury Stock Acquired, Average Cost Per Share 3 month | Treasury Stock Acquired, Average Cost Per Share 9 month | Treasury Stock Acquired, Average Cost Per Share 12 month |
|---|---|---|---|
| 2025-12-31 | $9.09 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $7.91 10-Q · filed 2025-11-05 | $7.91 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |